Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986590 | 0.84 | CSNK1A1 (0.47) | BTKCSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL986588 | 0.81 | CSNK1A1 (0.46) | BTKCSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL955818 | 0.76 | BTK (0.47) | BTKCSNK1A1TYRO3DYRK1BNPSR1 | |
| SCHEMBL985188 | 0.75 | PARP1 (0.38) | BTKCSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL15411215 | 0.74 | NPSR1 (0.36) | BTKNPSR1RXFP1GRM5PARP1 | |
| SCHEMBL29503449 | 0.73 | CSNK1A1 (0.58) | BTKCSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL28008449 | 0.73 | BTK (0.50) | BTKCSNK1A1TYRO3DYRK1BNPSR1 | |
| SCHEMBL15408910 | 0.71 | SQOR (0.34) | NPSR1RXFP1HTTL3MBTL1SQOR | |
| SCHEMBL30403779 | 0.71 | KDM4E (0.50) | BTKMAPK1HTTL3MBTL1 | |
| SCHEMBL2476969 | 0.71 | KDM4E (0.50) | BTKMAPK1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | BRD4, JAK2, JAK1 | BTK 6/4885CSNK1A1 1100/4885TYRO3 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.